MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-06-2026
The Cooper Companies Revenue 2011-2026 | COO
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue The Cooper Companies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.09 B | 3.9 B | 3.59 B | 3.31 B | 2.92 B | 2.43 B | 2.65 B | 2.53 B | 2.14 B | 1.97 B | 1.8 B | 1.72 B | 1.59 B | 1.45 B | 1.33 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.09 B | 1.33 B | 2.49 B |
Quarterly Revenue The Cooper Companies
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.02 B | - | 1.06 B | 1 B | 965 M | - | 1 B | 943 M | 932 M | - | 930 M | 877 M | 858 M | 49.3 M | 843 M | 830 M | 787 M | 2.16 B | 763 M | 720 M | 646 M | 682 M | 578 M | 525 M | 628 M | 692 M | 679 M | 654 M | 590 M | 652 M | 660 M | 631 M | 499 M | 562 M | 556 M | 522 M | 450 M | 519 M | 515 M | 484 M | 445 M | 456 M | 462 M | 435 M | 405 M | 468 M | 432 M | 412 M | 380 M | 412 M | 412 M | 384 M | 326 M | 396 M | 378 M | 345 M | 293 M | 361 M | 351 M | 325 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.16 B | 49.3 M | 620 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical instruments industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
169 M | - | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
21.8 B | $ 154.51 | -1.17 % | $ 44.4 B | USA |
 |
Luminex Corporation
LMNX
|
417 M | - | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
1.58 M | - | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
150 M | - | - | $ 955 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
12.8 M | $ 9.4 | -11.74 % | $ 22.8 M | USA |
 |
Cantel Medical Corp.
CMD
|
1.02 B | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
106 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
2.88 B | - | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
3.17 B | - | -0.02 % | $ 16.3 B | USA |
 |
Haemonetics Corporation
HAE
|
1.36 B | $ 56.83 | 1.05 % | $ 2.86 B | USA |
 |
Harvard Bioscience
HBIO
|
86.6 M | $ 5.2 | 2.16 % | $ 231 M | USA |
 |
ICU Medical
ICUI
|
2.23 B | $ 123.31 | -1.53 % | $ 3.04 B | USA |
 |
AngioDynamics
ANGO
|
292 M | $ 10.31 | -13.65 % | $ 421 M | USA |
 |
Isoray
ISR
|
3.55 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
10.1 B | $ 452.07 | -2.67 % | $ 161 B | USA |
 |
AtriCure
ATRC
|
535 M | $ 29.07 | 2.68 % | $ 1.39 B | USA |
 |
Repro Med Systems
KRMD
|
41.1 M | $ 4.32 | 1.17 % | $ 200 M | USA |
 |
InfuSystem Holdings
INFU
|
110 M | $ 9.29 | -0.11 % | $ 192 M | USA |
 |
iRhythm Technologies
IRTC
|
747 M | $ 116.8 | -1.2 % | $ 3.74 B | USA |
 |
Masimo Corporation
MASI
|
2.09 B | $ 178.59 | 0.33 % | $ 9.52 B | USA |
 |
BioLife Solutions
BLFS
|
82.3 M | $ 19.51 | 1.14 % | $ 899 M | USA |
 |
Merit Medical Systems
MMSI
|
1.52 B | $ 67.7 | -0.78 % | $ 4 B | USA |
 |
electroCore
ECOR
|
32 M | $ 6.8 | 3.03 % | $ 57.7 K | USA |
 |
OraSure Technologies
OSUR
|
115 M | $ 3.08 | 0.98 % | $ 226 M | USA |
 |
Glaukos Corporation
GKOS
|
315 M | $ 112.77 | 0.12 % | $ 5.46 B | USA |
 |
Pulse Biosciences
PLSE
|
350 K | $ 23.0 | -0.13 % | $ 1.55 B | USA |
 |
Predictive Oncology
POAI
|
125 K | - | - | $ 31.1 M | USA |
 |
Repligen Corporation
RGEN
|
632 M | $ 117.78 | -0.46 % | $ 6.56 M | USA |
 |
Baxter International
BAX
|
11.2 B | $ 16.68 | -0.6 % | $ 8.56 B | USA |
 |
ResMed
RMD
|
3.58 B | $ 224.09 | 0.56 % | $ 32.7 B | USA |
 |
NeuroMetrix
NURO
|
3.03 M | - | 5.05 % | $ 9.02 M | USA |
 |
STERIS plc
STE
|
5.46 B | $ 218.71 | -0.56 % | $ 21.6 B | USA |
 |
STAAR Surgical Company
STAA
|
239 M | $ 20.21 | 4.55 % | $ 1 B | USA |
 |
Stereotaxis
STXS
|
32.4 M | $ 1.87 | 1.08 % | $ 170 M | USA |
 |
Teleflex Incorporated
TFX
|
569 M | $ 117.81 | -0.52 % | $ 5.26 B | USA |
 |
Utah Medical Products
UTMD
|
9.04 M | $ 63.12 | 0.4 % | $ 205 M | USA |
 |
West Pharmaceutical Services
WST
|
3.07 B | $ 254.8 | 0.82 % | $ 18.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
3.68 B | $ 11.63 | -0.26 % | $ 2.32 B | USA |
 |
LeMaitre Vascular
LMAT
|
250 M | $ 108.49 | -0.24 % | $ 2.46 B | USA |
 |
Microbot Medical
MBOT
|
117 K | $ 2.4 | 1.27 % | $ 110 M |  Israel |
 |
Nephros
NEPH
|
14.2 M | $ 2.87 | -2.21 % | $ 29.8 M | USA |
 |
Envista Holdings Corporation
NVST
|
2.72 B | $ 25.81 | -0.35 % | $ 4.34 B | USA |
 |
Milestone Scientific
MLSS
|
8.97 M | $ 0.28 | -4.86 % | $ 23 M | USA |
 |
Alcon
ALC
|
10.4 B | $ 74.56 | -1.26 % | $ 40.4 B |  Schweiz |
 |
Pro-Dex
PDEX
|
66.6 M | $ 51.67 | 1.33 % | $ 170 M | USA |
 |
Retractable Technologies
RVP
|
38.3 M | $ 0.69 | 2.99 % | $ 20.7 M | USA |